Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Regular Aspirin Use Incurs Health Benefits

By HospiMedica International staff writers
Posted on 19 Aug 2014
A new study concludes that average-risk adults who used aspirin regularly for at least five years had a lower risk of cancer, myocardial infarction (MI), stroke, and premature death.

Researchers at Queen Mary, University of London (United Kingdom), the University of Milan (Italy), and other institutions reviewed current data and assessed the benefits and harms of prophylactic use of aspirin on colorectal, esophageal, stomach, pancreatic, lung, prostate, and breast cancer. More...
They also examined aspirin's effects on the risk of MI and stroke, and calculated the risk of gastrointestinal bleeding, peptic ulcer, and major extracranial bleeding.

The results showed that for average-risk individuals aged 50–65 years who had been taking aspirin for 10 years, there would be a relative reduction of between 7% (for women) and 9% (for men) in the number of cancer, MI, or stroke events over a 15-year period, and an overall 4% relative reduction in all deaths over a 20-year period; the largest and most consistent benefits were seen in colorectal cancer reduction. Excess bleeding was the most important harm associated with aspirin use, and its risk and fatality rate increased with age.

The researchers found that the effects of aspirin on cancer do not become apparent until at least three years after the start of use, and some benefits are sustained for several years after cessation in long-term users. No differences between low and standard doses of aspirin were observed, while higher doses did not confer additional benefit, but did increase toxicities. Doses between 75 and 325 mg/day appeared to have a favorable benefit–harm profile. The study was published online on August 5, 2014, in Annals of Oncology.

“It has long been known that aspirin, one of the cheapest and most common drugs on the market, can protect against certain types of cancer, but until our study, where we analyzed all the available evidence, it was unclear whether the pros of taking aspirin outweighed the cons,” said lead author Jack Cuzick, PhD, of Queen Mary, and colleagues. “Whilst there are some serious side effects that can't be ignored, taking aspirin daily looks to be the most important thing we can do to reduce cancer after stopping smoking and reducing obesity, and will probably be much easier to implement.”

Aspirin—acetylsalicylic acid—is a salicylate drug often used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. It has also been found effective at preventing certain types of cancer, particularly colorectal cancer. Aspirin also has an antiplatelet effect by inhibiting the production of thromboxane, which is one of the reasons it is used long-term, at low doses, to help prevent heart attacks, strokes, and blood clot formation in people at high risk.

Related Links:

Queen Mary, University of London
University of Milan



Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Digital Color Doppler Ultrasound System
MS22Plus
Emergency Ventilator
Shangrila935
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.